BenevolentAI Investor Conference Presentation Deck
Internal validation: pipeline generated from the
Benevolent Platform™
BEN-2293 | Atopic Dermatitis
BEN-8744 | Ulcerative Colitis
BEN-9160 | Amyotrophic Lateral Sclerosis
BEN-28010 | Glioblastoma Multiforme
Inflammatory Bowel Disease
Amyotrophic Lateral Sclerosis
Antiviral
Oncology
Oncology
Parkinson's Disease
Nonalcoholic Steatohepatitis
Oncology
Parkinson's Disease
Chronic Kidney Disease
Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Chronic Kidney Disease
+10 Exploratory stage programmes
Target ID
Hit to Lead Lead Opt Preclinical Phase I
AstraZeneca 27.01.2021
AstraZeneca 15.12.2021
AstraZeneca 17.05.2022
AstraZeneca 2 06.10.2022
AstraZeneca 06.10.2022
Phase II Phase III
BEN-2293 -
Phase Ib complete, Phase Ila ongoing
BEN-8744
Novel target - zero prior linkage to UC
2 years from target validation to
candidate selection
Broad disease coverage given platform
Balance of risk between "best in class"
and "first in class" drug candidates
Benevolent
11View entire presentation